Mathematical modeling suggests that starting lipid-lowering treatment at around age 40 provides the maximum event-free life years gained per year of treatment for individuals at moderate risk.
Does starting lipid lowering treatment at an earlier age based on relative risk improve lifetime cardiovascular events avoided compared to absolute risk thresholds?
Mathematical modeling suggests that waiting for absolute risk thresholds to be met before initiating lipid-lowering therapy allows significant lifetime cardiovascular risk to accumulate.
Coronary heart disease is the major cause of morbidity and mortality in industrialised countries. The Framingham cohort study has identified the quantitative impact of different risk factors and their interactions,1–3 and large intervention studies have confirmed that drug treatment to reduce risk factors decreases progression to heart attack and stroke.4 5 However, with this increased understanding have come additional problems. The treatments to reduce cholesterol concentrations or blood pressure are often expensive, and the population that might benefit is vast. Indeed if every individual who might benefit was treated with a statin or fibrate, a large portion of the total drugs budget would be consumed.6 Thus some form of rationing is inevitable, and various recommendations have emerged in an attempt to contain cost while targeting treatment at those who stand to gain the most. Current UK policy recommends treatment should be offered to anyone with an absolute annual risk of 3% or more.7 Others, however, favour a 1.5%-2% absolute threshold before beginning treatment, 8 9 and some have argued that estimates of relative risk should form the basis for treatment guidelines.10 Since age is the major determinant of absolute risk, treatment thresholds based on absolute risk will tend to postpone treatment to older age, whereas guidelines based on relative risk will tend to lead to treatment of younger people. #### Summary points Lipid lowering drugs are expensive and the population that might benefit from treatment is potentially vast Current guidelines recommend targeting treatment to those who will gain the most; gain being cardiovascular events avoided over a fixed period of 5 or 10 years Modeling of lifetime risk of cardiovascular disease suggests that many individuals will have accumulated most of their risk before they become eligible for treatment It is possible to predict an age at …
Silvia Ulrich (Sat,) conducted a other in Coronary heart disease. Lipid lowering treatment (statin) vs. No treatment or delayed treatment was evaluated on Event free life years gained per treatment year. Mathematical modeling suggests that starting lipid-lowering treatment at around age 40 provides the maximum event-free life years gained per year of treatment for individuals at moderate risk.